Step Pharma is a French biotechnology company developing novel therapeutics for haematological malignancies.
Step’s lead program focuses on a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 (cytidine triphosphate synthase 1). Humans with CTPS1 deficiency demonstrate an impaired capacity to proliferate T and B cells.
Step has identified novel, potent, selective, orally available inhibitors of CTPS1 and demonstrated potent anti-tumour activity in models of leukemia and lymphoma. Step’s first clinical candidate STP938 will enter clinical development in 2021.
Step Pharma is actively seeking new investors to join the existing syndicate to support our transformation into a clinical stage company.